---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-252071"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2021-08-20T23:59:59+00:00"
generated_at: "2026-06-29T08:43:08.861375+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics appoints Julie Burgess as Chief Accounting Officer

## Summary
- Julie Burgess appointed Chief Accounting Officer, effective September 13, 2021.
- Annual base salary of $350,000, bonus up to 35%, and stock option for 135,000 shares.
- Burgess previously SVP Finance at Otonomy; brings over 25 years of experience.
- Dawn Giangiulio will cease as interim principal accounting officer but remain Controller.

## SEC filing metadata
- accession: 0001193125-21-252071
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2021-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/d172325d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-252071
- JSON: https://secwatch.observer/filing/0001193125-21-252071.json
- Plain text: https://secwatch.observer/filing/0001193125-21-252071.txt

## Key facts
- Executive change
  Dawn Giangiulio changed role as Interim Principal Accounting Officer at Design Therapeutics, Inc..
  - Action: discontinue serving as
  - Role: Interim Principal Accounting Officer
  source text: Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm
- Executive change
  Julie Burgess was appointed as Chief Accounting Officer at Design Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Accounting Officer
  source text: On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.